Choosing the Appropriate Breast Cancer Therapy for Today's Breast Cancer Patient

Seminars in Oncology Nursing

Volumn 23, Issue SUPPL. 2, 2007, Pages

  Frankel, Cynthia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; FEMALE; GENETICS; HUMAN; MASTECTOMY; PATHOLOGY; PATIENT CARE PLANNING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; PATIENT CARE PLANNING; QUINAZOLINES; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2;

EID: 36549054021     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2007.10.002     Document Type: Article

References (44)

1. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles & practice of oncology (2007), Lippincott Williams & Williams, Philadelphia, PA
2. American Cancer Society. Cancer Facts & Figures 2007 (2007), American Cancer Society, Atlanta, GA
3. Clark M., Collins R., and Darby S. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
4. Lerner B.H. The breast cancer wars (2001), Oxford University Press, New York, NY
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer (2007), National Comprehensive Cancer Network, Jenkintown, PA
6. Fisher B., Dignam J., Wolmark N., et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16 (1998) 441-452
7. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
8. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
9. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 333 (1995) 1444-1455
10. Arriagada R., Le M.G., Rochard F., et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 14 (1996) 1558-1569
11. Arthur D.W., Morris M.M., and Vicini F.A. Breast cancer: new radiation treatment options. Oncology (Williston Park) 18 (2004) 1621-1629
12. Sanghani M., and Mignano J. Intensity modulated radiation therapy: a review of current practice and future directions. Technol Cancer Res Treat 5 (2006) 447-450
13. Stanford Cancer Center. Radiation Therapy. Available at: http://cancer.stanfordhospital.com/forPatients/services/radiationTherapy/respiratoryGating/default (accessed August 2, 2007).
14. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D^ metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 (2006) 113-121
15. NSABP study confirms Oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology (Williston Park) 20 (2006) 789-790
16. Kaklamani V.G., and Gradishar W.J. Gene expression in breast cancer. Curr Treat Options Oncol 7 (2006) 123-128
17. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
18. Pollack A. Test to predict breast cancer relapse is approved. New York Times. February 7, 2007.
19. Burstein H.J. The distinctive nature of HER2-positive breast cancers. N Engl J Med 353 (2005) 1652-1654
20. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
21. Herbst R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 suppl 2 (2004) 21-26
22. Baselga J., Perez E.A., Pienkowshi T., et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 (2006) 4-12
23. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
24. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
25. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
26. Tan-Chiu E., and Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 63 suppl 1 (2002) 57-63
27. Beslija S., Bonneterre J., Burstein H., et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18 (2006) 215-225
28. Xeloda package insert (2006), Roche Pharmaceuticals, Nutley, NJ
29. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
30. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
31. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18 (2000) 1399-1411
32. Jones S., Vogel C., Arkhipov A., et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17 (1999) 3418-3425
33. Herceptin package insert (2006), Genentech, Inc., South San Francisco, CA
34. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1 (2001) 85-94
35. Moy B., and Goss P.E. Lapatinib: current status and future directions in breast cancer. Oncologist 11 (2006) 1047-1057
36. Xia W., Bacus S., Hegde P., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 103 (2006) 7795-7800
37. Imai K., and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6 (2006) 714-727
38. Nahta R., Yu D., Hung M.C., et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3 (2006) 269-280
39. Roskoski Jr. R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319 (2004) 1-11
40. Chu I., Blackwell K., Chen S., et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65 (2005) 18-25
41. Tykerb prescribing information (2007), GlaxoSmithKline, Research Triangle Park, NC
42. US National Institutes of Health. Available at: http://www.clinicaltrials.gov/ct/action/ChangeQuery (accessed July 1, 2007).
43. Miller K.D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3 (2003) 421-422
44. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 suppl 3 (2005) 20-29